Scoping review explores interactions between stress granules and tau pathology, suggesting therapeutic potentials.
• SGs are associated with AD through bidirectional interactions with tau pathology, RNA dysregulation, and proteostatic collapse. • SG modulation is a potential therapeutic strategy for AD. • Autophagy enhancers (mTOR inhibitors, myricetin), show promise in reducing tau pathology.
No takes yet. Share an insight, caveat, or question.
Kashtiban et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: